It is known that patients with obesity, T2DM, and metabolic diseases tend to have high FGF21 levels but attenuated FGF21 signaling responses; therefore, previous research has further proposed that obesity, T2DM, and metabolic diseases are in an FGF21-resistant state13. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.